Compare MLCI & NMTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLCI | NMTC |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | 21 | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.4M | 29.2M |
| IPO Year | N/A | 2010 |
| Metric | MLCI | NMTC |
|---|---|---|
| Price | $3.07 | $1.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.90 |
| AVG Volume (30 Days) | 12.6K | ★ 48.6K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | N/A | ★ 80.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,097,692.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $31.90 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 163.47 |
| 52 Week Low | $2.68 | $0.55 |
| 52 Week High | $8.68 | $5.40 |
| Indicator | MLCI | NMTC |
|---|---|---|
| Relative Strength Index (RSI) | 40.49 | 22.75 |
| Support Level | $2.70 | $0.67 |
| Resistance Level | $3.13 | $3.41 |
| Average True Range (ATR) | 0.13 | 0.22 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 6.56 | 8.12 |
Mount Logan Capital Inc operates as emerging asset management and investment firm focused on investing in public and private debt securities in the North American market. The company's reporting segments include asset management and insurance. The company through its subsidiaries, earns management and incentive fees and servicing fees for providing investment management, monitoring and other services to investment vehicles and advisers. The Asset Management segment comprises all fee generating activities. The Insurance Solutions segment, which derives maximum revenue, consists of two product lines within the insurance business, LTC and MYGA.
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.